Activity and specificity of chemotherapeutic agents against solid tumors can be augmented via the targeted or localized delivery of 'suicide' genes. Selective activation of specific prodrugs in cells expressing the 'suicide' gene drives their elimination by apoptosis, while also enabling the killing of adjacent bystander cells. Strong bystander effects can compensate for poor 'suicide' gene delivery, and depend on the prodrugs used and mechanisms for the acquisition of activated drug by the bystander population, such as the presence of gap junctional intercellular communications. Although a number of 'suicide' gene therapies for cancer have been developed and characterized, such as herpes simplex virus-derived thymidine kinase (HSVtk)-based activation of ganciclovir, their limited success highlights the need for the development of more robust approaches. Limiting activation kinetics and evolution of chemoresistance are major obstacles. Here we describe 'suicide' gene therapy of cancer based on the lentivirus-mediated delivery of a thymidine-active human deoxycytidine kinase variant. This enzyme possesses substrate plasticity that enables it to activate a multitude of prodrugs, some with distinct mechanisms of action. We evaluated the magnitude and mechanisms of bystander effects induced by different prodrugs, and show that when used in combination, they can synergistically enhance the bystander effect while avoiding off-target toxicity.
INTRODUCTION
Conventional chemotherapy is a standard treatment for malignant tumors. However, tumor cells are highly heterogeneous with respect to their sensitivity towards most chemotherapeutic agents.
1,2 Therefore, enhancing chemotherapy via the delivery of specific 'suicide' genes, which potentiate the rapid activation of select chemotherapeutic agents, has been explored for the treatment of solid tumors. 3 --5 The targeted or localized delivery of 'suicide' genes into tumor cells not only greatly augments their sensitivity to select prodrugs, but also avoids the peripheral toxicity common to the use of those chemotherapeutic agents. Furthermore, delivery of the 'suicide' gene to all cells in the tumor is unnecessary if bystander cell killing takes place with the particular 'suicide' gene/prodrug combination. 5, 6 Such is the case with the most commonly utilized 'suicide' gene, herpes simplex virus-derived thymidine kinase (HSV-tk), which can activate the prodrugs ganciclovir (GCV) and acyclovir (ACV). 7 --9 Classically, if cancer cells are connected by functional gap junctional intercellular communications (GJICs), GCV activated in cells expressing HSV-tk can diffuse into neighboring bystander cells not expressing HSV-tk and kill them as well. 6, 10 This phenomenon is known as the bystander effect.
The efficiency of delivery of genes into tumor cells is a major obstacle to successful direct 'suicide' gene therapy of cancer. 9,11 --13 Poor gene delivery is thought to be attributed to the combination of inefficient intratumoral injections of the delivery vehicles and the distribution-limiting nature of tumor vasculature and microenvironment. Consequently, only a portion of tumor cells ultimately receive the transgene, resulting in a marbled 'suicide' gene expression pattern.
14 Therefore, bystander effects must contribute significantly to the overall anti-tumor activity of different 'suicide' gene therapies of cancer, including the HSVtk/GCV-based approaches.
Despite utilization in clinical protocols, 9 HSV-tk-based 'suicide' gene therapy suffers from a number of disadvantages. In particular, poor prodrug activation kinetics, 15, 16 limited cell toxicity mechanisms, 17 evolution of drug resistance, 18, 19 and prophylactic use of GCV in the clinic 20 impact broad implementation of that approach. Furthermore, the poor lipophilicity of the hydrophilic GCV and its reduced ability to penetrate the blood --brain barrier are considered limiting in HSV-tk/GCV-based applications targeted to the brain in the clinic. 12, 21 Taken together, these limitations prompt the development of novel and improved 'suicide' gene therapy strategies for enhancing the treatment of solid tumors that also facilitate strong bystander effects.
Here we describe a next-generation modality for 'suicide' gene therapy of cancer based on lentivirus (LV)-mediated delivery of active site-engineered human deoxycytidine kinase (dCK). This mutant kinase is able to activate a variety of nucleoside analog (NA)-based prodrugs with different mechanisms of action and possesses robust activation kinetics. Wild-type dCK is a key kinase in the cell and is able to phosphorylate deoxyadenosine (dA), deoxyguanosine (dG), and deoxycytidine (dC) nucleosides, but not deoxythymidine (dT) or deoxyuridine (dU). Activation of a number of chemotherapeutic agents, such as cytarabine, gemcitabine and clofarabine, is mediated by dCK, 22 and it is also uniquely capable of activating nucleosides with the nonphysiological L-chirality. 23 The dCK variant utilized herein contains three amino-acid mutations from wild-type. Mutation of Arg104 to Met104 (R104M) coupled with the Asp133 to Ala133 (D133A) mutation renders dCK thymidine active. 24, 25 The dCK.R104M.D133A double mutant (dCK.DM) is capable of phosphorylating such prodrugs as bromovinyl-deoxyuridine (BVdU), L-deoxythymidine (LdT) and L-deoxyuridine (LdU), which are not substrates for wild-type dCK, with high catalytic efficiency. 25 Finally, the Ser74 to Glu74 (S74E) mutation mimics phosphorylation at the Ser74 residue, further increasing the activity of mutant dCK in cells where dCK activity is regulated by phosphorylation of this residue. 26 The LV-mediated delivery of dCK.DM.S74E mutant into a variety of cell types dramatically increases their sensitivity to BVdU, LdT and LdU. 27 Additionally, cells expressing dCK.DM.S74E can be directly visualized in situ by microPET imaging, providing the capacity to monitor 'suicide' gene therapy delivery and progress. 28 Here we explored this mutant dCK for use in 'suicide' gene therapy of cancer, and investigated the efficiency and mechanisms of bystander cell killing with dCK.DM.S74E-active prodrugs in vitro and in vivo. Brain tumors are particularly difficult to treat even by a combination of surgery, radiotherapy and chemotherapy. We have therefore utilized the U87mg human glioblastomaastrocytoma cell line, which was previously documented to exhibit bystander effects, 29, 30 for our in vitro and in vivo studies. In addition to enabling the use of multiple dT and dU NAs for 'suicide' gene therapy of cancer, dCK.DM.S74E retains its ability to potentiate the activation of traditional chemotherapeutic agents, such as cytarabine (AraC) and gemcitabine (Gem). 25 To take advantage of the multivariate nature of the 'suicide' gene, we have further evaluated whether combinations of two or more mutant dCK-active prodrugs can act synergistically to enhance bystander cell killing.
MATERIALS AND METHODS

Construction of LV expression vectors and production of high-titer virus
The plasmids containing the cDNAs for wild-type dCK and dCK.R104M.D133A were previously described. 24 Recombinant LVs for the expression of wild-type dCK and the R104 M.D133A dCK double mutant (DM) were constructed by first subcloning the corresponding dCK cDNA into the bicistronic pSV-IRES-huCD19D vector, also described previously. 31 The resulting dCK-IRES-huCD19D cassette was then subcloned downstream of the EF1-a promoter in our HIV1-based recombinant LV expression plasmid, pHR'-cPPT-EF-WPRE-SIN, described previously. 32 The resulting pHR'-EF-dCK.DM-WPRE-SIN vector was then modified by sitedirected mutagenesis (QuikChange II XL Site-Directed Mutagenesis Kit, Stratagene, La Jolla, CA) to generate the pHR'-EF-dCK.DM.S74E-WPRE-SIN vector encoding the R104M.D133A.S74E dCK triple-mutant (DM.S74E) cDNA. 24 The mutagenesis primers used were: S74E forward 5 0 -CAAGAT GAATTTGAGGAACTTACAATGGAGCAGAAAAATGGTGGGAATGTTC-3 0 and S74E reverse 5 0 -GAACATTCCCACCATTTTTCTGCTCCATTGTAAGTTCCTCA AATTCATCTTG-3 0 . The LV vector encoding the control enhanced green fluorescent protein (eGFP) cDNA, pHR'-EF-eGFP-WPRE-SIN, was described previously. 32 Fidelity of all constructs was confirmed by sequencing. VSVg-pseudotyped LVs were generated by transient transfection of 293T cells (ATCC, Manassas, VA, Canada) with PEI (Sigma, Oakville, ON, Canada) using a three-plasmid system (pHR' plasmid construct, packaging plasmid pCMVDR8.91 packaging plasmid, and the pMD.G VSV-g expression plasmid). Viral supernatant was harvested, concentrated by ultracentrifugation, assessed for titer and stored until use as described previously. 31 Cell culture and transduction of cell lines Analysis of Connexin43/GJA1 protein expression by immunocytofluorescence A total of 2 Â 10 4 non-transduced U87mg cells were plated per well in a Lab-Tek 16 Chamber Glass Slide for cell culture (Thermo Fischer Scientific, Nepean, ON, Canada) and cultured overnight allowing the cells to adhere. Media was removed from the cells, wells were washed twice with phosphatebuffered saline (PBS), and 2 mM PKH26 in 100 ml of Diluent C (Sigma) was added directly to stain the plasma membrane. Following a 5-min incubation, the staining was quenched with 100 ml of fetal bovine serum for 1 min. Cells were then washed twice with PBS and fixed with 4% paraformaldehyde in PBS for 10 min. Fixed cells were washed three times with PBS and blocked with 1% bovine serum albumin in PBS for 10 min. Fixed cells were stained for 1 h at room temperature with the primary rabbit antiConnexin43/GJA1 polyclonal antibody (Abcam, Cambridge, MA) diluted to 5 mg ml
À1
, then washed three times with PBS. Cells were then simultaneously stained with the secondary Alexa Fluors 488 Goat anti-Rabbit IgG (H þ L) antibody (Invitrogen; diluted 1:400) and 1 mM 4 0 ,6-diamidino-2-phenylindole (Invitrogen) for 1 h at room temperature, and then washed three times with PBS. The slide was then covered with Dako Fluorescence Mounting Medium (Dako, Markham, ON, Canada), sealed, and visualized on the Zeiss Axioskop 2 fluorescent microscope equipped with acquisition camera and software (Carl Zeiss Canada, Toronto, ON, Canada).
Analysis of Connexin43/GJA1 protein expression by Western blotting
A total of 5 Â 10 6 non-transduced, dCK-transduced and eGFP-transduced U87mg cells were lysed by boiling in reducing Laemmli lysis buffer, resolved by a 10% SDS --polyacrylamide gel electrophoresis, and transferred onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA) by semi-dry transfer following the manufacturer's instructions. The membrane was blocked overnight at 4 1C (with shaking) in PBS-T (0.1% Tween-20 v/v in PBS) with 5% w/v non-fat dry milk (NFDM). The membrane was stained for 2 h at room temperature with a rabbit anti-Connexin43/ GJA1 polyclonal antibody (Abcam) diluted to 1 mg ml À1 in PBS-T with 5% w/v NFDM, washed with PBS-T, and then stained for 2 h at room temperature with secondary stabilized goat anti-rabbit IgG (H þ L) conjugated to horseradish peroxidase (Thermo Fischer Scientific) diluted 1:2500 in PBS-T with 5% w/v NFDM. Following washing with PBS-T, the membrane was then developed with Western Lightning Plus Enhanced Chemiluminescence Substrate (Perkin Elmer, Woodbridge, ON, Canada) following the manufacturer's instructions and exposed onto Kodak X-Omat LS Film (Sigma). 
Determination of apoptosis induction in bystander cells by prodrug activation in vitro
Non-transduced or dCK-transduced U87mg cells were mixed with eGFPtransduced cells in different ratios and plated at a total of 2 Â 10 5 cells per well in 6-well tissue culture plates. Cells were then cultured in the presence or absence of optimal concentrations 27 of 100 Analysis of bystander cell killing in a transwell culture assay A total of 1 Â 10 5 eGFP-positive U87mg cells were plated and cultured in a 1:1 ratio with 1 Â 10 5 dCK-transduced or non-transduced cells in a 6-well plate format as above. Alternatively, 1 Â 10 5 eGFP-positive cells were plated and cultured in a transwell (0.4 mm pore size; BD Falcon, Mississauga, ON, Canada), while dCK-transduced or non-transduced cells were cultured in the well, and vice versa. Cells were cultured in the presence or absence of 100 mM BVdU for a period of 3 days. Following treatment, cells were collected and induction of apoptosis in eGFP-positive and -negative cell populations was assessed by Annexin-V staining and flow cytometric analyses as above.
Analysis of bystander cell killing in the presence of gap junction inhibitors
U87mg eGFP-positive cells were mixed in a 4:1 ratio with dCK-transduced or non-transduced cells and plated at a total of 2 Â 10 5 cells per well in a 6-well plate format as above. Cells were cultured in the presence or absence of 100 mM BVdU, as well as in the presence or absence of either 35 mM 18-bglycyrrhetinic acid (18G; Sigma) or 100 mM carbenoxolone (CRBX; Sigma) for a period of 3 days. Following treatment, cells were collected and induction of apoptosis in eGFP-positive and -negative cell populations was assessed by Annexin-V staining and flow cytometric analyses as above.
Subcutaneous tumor model in non-obese/diabetic severe combined immunodeficient mice All experimental procedures involving animals were carried under a protocol approved by the Animal Care Committee of the University Health Network (Toronto, ON, Canada). Non-obese/diabetic severe combined immunodeficient (NOD/SCID) mice (male, 6 --10 weeks old) were maintained at the Animal Resource Centre at the Princess Margaret Hospital (Toronto, ON, Canada). Mice were injected on day 0 into the right dorsal flank with a 1: 
RESULTS
Development of polyclonal U87mg cell lines expressing dCK. DM.S74E or eGFP transgenes
The constructs utilized in this study for LV-mediated gene transfer are diagrammed in Figure 1a . We used a bicistronic orientation we have employed previously. 31 U87mg cells were transduced with recombinant LV engineering the expression of either dCK.DM.S74E and the cytoplasmic tail-truncated human CD19 cell surface marker or eGFP at a multiplicity of infection of 20. Transduced cells were subsequently enriched by two rounds of FACS (Figure 1b) for either high-truncated human CD19 marker expression or high eGFP expression, respectively.
Expression of Connexin43/GJA1 protein in U87mg cells U87mg cells have been reported to express the gap junction protein Connexin43/GJA1 in their cell membrane as the major type of GJIC. 33 To confirm Connexin43 expression on the U87mg cell line in our hands, we labeled U87mg cell monolayers with an antibody directed at an N-terminal epitope of Connexin43 and analyzed its expression by immunocytofluorescence. Figure 1c depicts the localization of Connexin43 staining (green) with the plasma membrane visualized with the PKH26 dye that partitions into the lipid bilayer (red). To confirm that the transduction and enrichment of U87mg cells did not diminish Connexin43 expression, we analyzed cell lysates from our transduced U87mg cells lines by western blotting with an anti-human Connexin43 antibody. Figure 1d demonstrates that all three cell line populations derived in this study retained Connexin43 expression after long-term culture.
Small molecules can be exchanged between cells in U87mg coculture monolayers The bystander effect relies on the ability of small (o1 kDa) molecules of activated drug to traverse into neighbouring cells via gap junctions down a concentration gradient. We have set up a dye-transfer experiment to validate this in our U87mg monolayer cultures. The cell membrane-permeant AM ester of the Calcein Red dye is rapidly hydrolyzed inside the cell to form a charged fluorescent molecule that is unable to cross the cell membrane and is trapped in the cytoplasm. When Calcein AM Red-loaded U87mg cells were cocultured in a 1:1 ratio with eGFP-positive U87mg cells for a period of 2 days, the Calcein Red dye was able to migrate and accumulate significantly in eGFP-positive cells (Figure 2a) . After 3 days, 470% of the bystander eGFP-positive cell population accumulated significant quantities of the Calcein Red dye (Figure 2b ), but no substantial eGFP transfer to Calcein Red-positive cells was observed. The dye-transfer experiments Engineered dCK for suicide gene therapy of cancer A Neschadim et al confirmed that functional GJIC channels are formed between our transduced U87mg cells in the monolayer culture.
Ratio of the 'suicide' gene transduced cells to bystander cells determines the magnitude of the bystander effect in vitro
Transduction efficiency is one major limiting factor of 'suicide' gene therapy of cancer that relies on a strong bystander effect. As such, we wanted to approximate what minimal percentage of dCK.DM.S74E-transduced cells would be required to obtain a strong bystander effect. We mixed dCK.DM.S74E-transduced U87mg cells at different ratios with eGFP-transduced cells, and evaluated the induction of apoptosis in bystander cells following a 3-day treatment with the prodrug BVdU. We used the optimal concentration of BVdU (100 mM) that we established previously (EC 50 for BvdU-mediated killing in dCK.DM.S74E-transduced U87mg is 0.3 mM), 27 defined as the concentration at which strong cytotoxicity is observed in dCK.DM.S74E-transduced cells with no significant toxicity in wild-type cells. As the proportion of dCKtransduced cells increased in the coculture, so did the apoptotic (Figure 3a) . As well, the apoptotic index of U87mg dCK.DM.S74E-transduced cells themselves progressively increased with the increase in their proportion in the coculture (Figure 3a) . This suggested that the loss of activated BVdU metabolites to bystander cells reduced the effective drug concentrations in dCK-transduced cells themselves as the proportion of bystander cells increased.
In addition to BVdU, two other dCK.DM.S74E-active prodrugs, LdT and LdU, also show significant bystander effects when the transduced population is present in at least a 20% proportion in cocultures (Figure 3b) . Because of somewhat distinct mechanisms of action of activated BVdU and LdT/LdU drugs, 34, 35 it was of interest to investigate whether combination treatment with two or more of these prodrugs would enhance the bystander cell killing in vitro. Indeed, the treatment of U87mg cocultures containing 20% dCK-transduced cells and 80% eGFP-transduced cells with a combination of BVdU and LdT or BVdU with both LdT and LdU, could overcome the plateau observed previously and elicit a strong synergistic bystander effect (Figure 3b ). Despite the increased total concentration of prodrugs used, no significant increase in toxicity was observed in control cocultures of non- transduced and eGFP-transduced cells treated with all three prodrugs together (Figure 3b ).
Bystander cell killing requires direct cell-to-cell contact in vitro
Next we wanted to demonstrate that the bystander effect we observed in dCK-transduced U87mg cells was indeed due to gap junction-mediated transfer of activated antimetabolites 10, 30 and not due to another mechanism, such as the fusion of apoptotic vesicles derived from drug-killed 'effector' cells with the bystander cells.
36 U87mg dCK-transduced or non-transduced cells were either cocultured with eGFP-transduced cells directly, or cultured in a transwell system. Figure 4a shows that a strong bystander effect was elicited by BVdU activation in direct cocultures of dCKtransduced and eGFP-transduced cells that allowed for cell --cell contact, as expected. However, no bystander effect could be observed when the two populations where cultured separated by a transwell 0.4-mm membrane, which allows the passage of small and large particles across, but precludes cell --cell contact or cell migration (Figure 4a ). Exosomes and apoptotic vesicles are typically sized between 30 nm and 500 nm, and can pass relatively freely through a 0.4-mm membrane, suggesting that, although they could enhance the bystander effect in some cell lines, 36 they were not a major factor in our U87mg cell analyses.
Inhibitors of gap junctions abrogate bystander cell killing in vitro We reasoned that if gap junction-mediated transfer of activated antimetabolites was primarily responsible for the bystander cell killing observed in our hands with U87mg cells, then pharmacological inhibition of GJICs would abrogate that effect. As demonstrated in Figure 4b , coculture of U87mg dCK-transduced and eGFP-transduced cells in the presence of either 18-bglycyrrhetinic acid 37 or carbenoxolone, 38 which are inhibitors of GJIC, significantly reduced the bystander effect mediated by activated BVdU in vitro. This reinforces that the bystander effect in U87mg cocultures is mostly mediated by GJIC. productively transduced cells is present in the tumor at the initiation of the drug treatment, and thus if they themselves are eliminated too quickly, the duration and the magnitude of the bystander effect is inadequate to substantially reduce the overall tumor burden. DISCUSSION HSV-tk/GCV-based 'suicide' gene therapy of cancer has been extensively characterized in vitro, in animal models, and in clinical trials aimed at treating solid tumors. 9 These investigations have highlighted deficiencies of both the HSV-tk enzyme and the GCV prodrug in application to 'suicide' gene therapy, and outlined the need for novel systems that are capable of robust activation of other potent prodrugs. One such system is described here in its application to the treatment of solid tumors. The thymidine-active mutant of dCK, dCK.DM.S74E, is capable of potentiating the activation of multiple prodrugs, including the BVdU, LdT, and LdU NAs with high selectivity. Furthermore, activation of these drugs by mutant dCK in transduced cells allows them to elicit strong bystander effects in the context of cell monolayers in vitro and solid tumors in vivo.
Evolution of chemotherapy resistance in cancer cells typically arises due to reduction of pro-apoptotic factors, reduction in the expression of specific genes responsible for activation of the chemotherapeutic agents, and increases in multidrug resistance efflux pumps. Furthermore, specific resistance to several NA-based chemotherapeutic agents is associated with a decrease in the expression or activity of dCK, the central enzyme to their activation in the cell. 39 Such is the case with gemcitabine, a potent chemotherapeutic agent with primary utilization in the treatment of pancreatic cancer. 40 Therefore, the overexpression of a dCK mutant capable of phosphorylating these chemotherapeutic agents in tumor cells is also of particular interest to sensitize or resensitize them to these drugs.
Cancer cells also develop resistance to chemotherapeutic agents by upregulating the expression of membrane efflux pumps known as multidrug resistance-associated proteins. A very prominent multidrug resistance-associated protein is the multidrug resistance transport protein MDR1, or P-glycoprotein, a member of the ABC transporter superfamily. 41 It is capable of removing small hydrophobic or positively charged molecules from the cytoplasm of the cell in an ATP-dependent manner, preventing their accumulation to therapeutically effective concentrations. Intrinsic or acquired amplification of the MDR1 gene is implicated in resistance to many common chemotherapeutic agents in a variety of cancers. In a screen of anti-recombinagenic substances, BVdU was shown to prevent the amplification of the MDR1 gene induced by the treatment with other chemotherapeutic agents, when given as a pretreatment or in combination with such agents as adriamycin, mitoxantrone, doxorubicin or mitomycin C. 42, 43 These findings resulted in the initiation of several early trials, 44 and a Phase II efficacy clinical trial of gemcitabine given in combination with BVdU in pancreatic cancer patients. 45 Although the latter study was halted in 2009 on the recommendation of the overseeing Data Safety Monitoring Committee, detailed safety and efficacy analyses have yet to be conducted on the unblinded data. Although BVdU is known to be well-tolerated and has a safe clinical profile, 46, 47 it is likely that gemcitabine-induced adverse events were limiting or the efficacy endpoints could not be met in this particular study. Thus, in the context of preventing multidrug resistance, sensitizing cancer cells to apoptosis, and enhancing chemotherapy, BVdU could greatly benefit from a specific cancer gene therapy approach targeted to solid tumors, such as the delivery of the BVdU-activating dCK mutant described here. Interestingly, another dCK substrate, lamivudine or 3TC, was also recently shown to inhibit multidrug resistance-associated proteins and enhance the effects of conventional chemotherapy. 48 Finally, BVdU is more lipophilic than GCV, 21 and is better suited for applications targeted to brain tumors that rely on significant passage of the therapeutic prodrug across the blood --brain barrier.
Efficient delivery of 'suicide' genes to tumor cells is a major obstacle to successful cancer therapy, and the need for strong bystander effects has been highlighted by scores of studies of therapies for solid tumors. We have shown here that synergistic increases in the magnitude of the bystander effect can be achieved via simultaneous activation of more than one prodrug, without necessarily increasing off-target toxicity. Strategies taking advantage of multiple cell-killing pathways targeted by different prodrugs via delivering more than one 'suicide' gene have often yielded increased efficacy. 49, 50 However, from a practical perspective, given the safety concerns associated with various delivery vehicles for gene therapy and transgenes, and the resulting stringent regulatory requirements for translation into the clinic, the use of multiple 'suicide' genes is hardly justified when alternative approaches based on a single gene with high prodrug plasticity, such as the dCK.DM.S74E mutant, are available.
We have demonstrated here that the dCK.DM.S74E 'suicide' gene can be useful in cancer gene therapy of solid tumors. It activates a multitude of NA-based prodrugs, it does so with robust catalytic efficiency, and it permits strong bystander effects. The substrate plasticity of this mutant enzyme is a unique feature of this 'suicide' system, and permits the use of such potent drugs as BVdU, which mediate effective bystander cell killing, reduce chemoresistance and are suited for applications in a variety of cancers. Finally, the imaging capabilities of this system 28 enable monitoring therapy progress by PET in situ, as well as providing a level of control over the dosing and delivery of the 'suicide' gene into tumors in vivo.
